Search Results - "Yaeger, R"

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer by Ambrosini, M, Rousseau, B, Manca, P, Artz, O, Marabelle, A, André, T, Maddalena, G, Mazzoli, G, Intini, R, Cohen, R, Cercek, A, Segal, N H, Saltz, L, Varghese, A M, Yaeger, R, Nusrat, M, Goldberg, Z, Ku, G Y, El Dika, I, Margalit, O, Grinshpun, A, Murtaza Kasi, P, Schilsky, R, Lutfi, A, Shacham-Shmueli, E, Khan Afghan, M, Weiss, L, Westphalen, C B, Conca, V, Decker, B, Randon, G, Elez, E, Fakih, M, Schrock, A B, Cremolini, C, Jayachandran, P, Overman, M J, Lonardi, S, Pietrantonio, F

“…POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific…”
Get more information

Progressive plasticity during colorectal cancer metastasis by Moorman, A R, Benitez, E K, Cambuli, F, Jiang, Q, Mahmoud, A, Lumish, M, Hartner, S, Balkaran, S, Bermeo, J, Asawa, S, Firat, C, Saxena, A, Wu, F, Luthra, A, Burdziak, C, Xie, Y, Sgambati, V, Luckett, K, Li, Y, Yi, Z, Masilionis, I, Soares, K, Pappou, E, Yaeger, R, Kingham, P, Jarnagin, W, Paty, P, Weiser, M R, Mazutis, L, D'Angelica, M, Shia, J, Garcia-Aguilar, J, Nawy, T, Hollmann, T J, Chaligné, R, Sanchez-Vega, F, Sharma, R, Pe'er, D, Ganesh, K

“…As cancers progress, they become increasingly aggressive-metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire…”
Get full text

O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer by Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz Casado, A., Graham, J., Kato, T., Ruffinelli, J., André, T., Carriere Roussel, E., Klauck, I., Groc, M., Grothey, A., Vedovato, J., Tabernero, J.

Get full text

ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC) by Grothey, A., Yaeger, R., Paez, D., Tabernero, J., Taïeb, J., Yoshino, T., Groc, M., Vedovato, J., Chetaille, E., Van Cutsem, E.

Get full text

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer by Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A., Maharry, K., Loupakis, F., Hong, Y., Steeghs, N., Guren, T., Arkenau, H., García Alfonso, P., Sandor, V., Christy-Bittel, J., Anderson, L., Tabernero, J.

Get full text

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer by Van Cutsem, E., Cuyle, P., Huijberts, S., Schellens, J., Elez, E., Yaeger, R., Fakih, M., Montagut, C., Peeters, M., Desai, J., Yoshino, T., Ciardiello, F., Wasan, H., Maharry, K., Christy-Bittel, J., Gollerkeri, A., Kopetz, S., Grothey, A., Tabernero, J.

Get full text

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer by Grothey, A., Tabernero, J., Taieb, J., Yaeger, R., Yoshino, T., Maiello, E., Fernandez, E. Elez, Casado, A. Ruiz, Ross, P., André, T., Kato, T., Ruffinelli, J., Graham, J., den Eynde, M. Van, Vera, R., Jean, B., Roussel, E. Carriere, Cahuzac, C., Issiakhem, Z., Vedovato, J., Cutsem, E. Van

Get full text

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study by Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S.

“…Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer…”
Get full text

Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short‐term outcomes by Roxburgh, C. S. D., Strombom, P., Lynn, P., Cercek, A., Gonen, M., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Shia, J., Vakiani, E., Yaeger, R., Stadler, Z. K., Segal, N. H., Reidy, D., Varghese, A., Wu, A. J., Crane, C. H., Gollub, M. J., Saltz, L. B., Garcia‐Aguilar, J., Weiser, M. R.

“…Aim Significant recent changes in management of locally advanced rectal cancer (LARC) include preoperative staging, use of extended neoadjuvant therapies and…”
Get full text

Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically? by Dos Santos Fernandes, G., Chatila, W., Yaeger, R., Mendelsohn, R., Stadler, Z., Segal, N.H., Varghese, A., Reidy, D., Diaz, L., Shia, J., Vakiani, E., Hechtman, J., Schultz, N., Berger, M., Hyman, D., Solit, D., Saltz, L., Garcia Aguilar, J., Cercek, A.

Get full text

Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy by Cercek, A, Dos Santos Fernandes, G, Roxburgh, C, Ng, S, Yaeger, R, Segal, N, Ganesh, K, Reidy, D, Smith, J J, Nash, G, Guillem, J, Paty, P, Shia, J, Garcia-Aguilar, J, Diaz, L, Crane, C, Goodman, K, Saltz, L, Weiser, M, Stadler, Z

Get full text

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC by Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.-T., Garcia-Alfonso, P., Belani, A., Zhang, X., Tabernero, J.

“…In the BEACON CRC study (NCT02928224), encorafenib plus cetuximab with binimetinib {9.3 versus 5.9 months; hazard ratio (HR) [95% confidence interval (CI)]:…”
Get full text

KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver by Popovic, M., Talarico, O., van den Hoff, J., Kunin, H., Zhang, Z., Lafontaine, D., Dogan, S., Leung, J., Kaye, E., Czmielewski, C., Mayerhoefer, M. E., Zanzonico, P., Yaeger, R., Schöder, H., Humm, J. L., Solomon, S. B., Sofocleous, C. T., Kirov, A. S.

“…Background Deriving individual tumor genomic characteristics from patient imaging analysis is desirable. We explore the predictive value of 2-[18F]FDG uptake…”
Get full text

2189 Early onset colorectal cancer - does the difference lie in epigenetics? by Ben-Aharon, I, Pelossof, R, Elkabets, M, Battaglin, F, Goodman, K, Yaeger, R, Saltz, L, Schultz, N, Solit, D, Garcia-Aguilar, J, Cercek, A

Get full text

Characterization of Rectal Cancer in Patients With Lynch Syndrome by Ng, S.Y, Shia, J, Cercek, A, Segal, N, Reidy, D, Yaeger, R, Nash, G, Temple, L.K.F, Weiser, M, Kelsen, D, Gaddam, P, Lincoln, A, Markowitz, A, Robson, M, Offit, K, Paty, P, Guillem, J.G, Saltz, L, Goodman, K.A, Stadler, Z

Get full text

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer by Tabernero, J, van Geel, R, Bendell, J.C, Spreafico, A, Schuler, M, Yoshino, T, Delord, J.P, Yamada, Y, Lolkema, M.P, Faris, J.E, Eskens, F.A.L.M, Sharma, S, Yaeger, R, Lenz, H.J, Wainberg, Z, Avsar, E, Chatterjee, A, Jaeger, S, Demuth, T, Schellens, J.H.M

Get full text

P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer by Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravergna, G., Bencardino, K., Cercek, A., Chen, C., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., di Nicolantonio, F., Solit, D., Bardelli, A.

Get full text

Ramp wear and debris from load/unload lift-tab roughness by Yaeger, J.R.D.

“…The technique of Suk et al. (1999) is used to measure in-situ wear and debris generation versus suspension lift-tab roughness during ramp load/unload on a…”
Get full text

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer by Strickler, John H., Satake, Hironaga, George, Thomas J., Yaeger, Rona, Hollebecque, Antoine, Garrido-Laguna, Ignacio, Schuler, Martin, Burns, Timothy F., Coveler, Andrew L., Falchook, Gerald S., Vincent, Mark, Sunakawa, Yu, Dahan, Laetitia, Bajor, David, Rha, Sun-Young, Lemech, Charlotte, Juric, Dejan, Rehn, Marko, Ngarmchamnanrith, Gataree, Jafarinasabian, Pegah, Tran, Qui, Hong, David S.

“…In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a…”
Get full text

Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins by Keenan, Terence, Yaeger, David R., Courage, Nancy L., Rollins, Carl T., Pavone, Mary Ellen, Rivera, Victor M., Yang, Wu, Guo, Tao, Amara, Jane F., Clackson, Tim, Gilman, Michael, Holt, Dennis A.

“…The total synthesis and in vitro activities of a series of chemical inducers of dimerization (CIDs) is described. The use of small-molecule CIDs to control the…”
Get full text